SCHEMBL25195367

SCHEMBL25195367

O=c1oc(-c2ccc(O)c(Cl)c2)nc2sc3c(c12)CCCC3

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.65
MAPT P10636 8/20 0.65
ALDH1A1 P00352 6/20 0.65
HPGD P15428 6/20 0.65
RAB9A P51151 4/20 0.65
NFKB1 P19838 1/20 0.65
NFKB2 Q00653 1/20 0.65
RELA Q04206 1/20 0.65
KMT2A Q03164 5/20 0.61
CASP3 P42574 3/20 0.61
MEN1 O00255 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
POLB P06746 2/20 0.61
PLA2G1B P04054 1/20 0.61
BLM P54132 1/20 0.61
CASP6 P55212 1/20 0.61
CASP8 Q14790 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30500265 1.00 SMN1; SMN2 (0.65) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL914016 0.79 SMN1; SMN2 (0.77) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL912737 0.79 SMN1; SMN2 (1.00) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL914037 0.77 SMN1; SMN2 (0.77) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL914213 0.77 SMN1; SMN2 (0.77) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL913600 0.77 SMN1; SMN2 (1.00) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL913965 0.76 SMN1; SMN2 (0.72) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL913313 0.75 SMN1; SMN2 (0.70) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL914596 0.75 MAPT (0.77) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL3916315 0.74 SMN1; SMN2 (0.76) SMN1; SMN2MAPTALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 US disclosed
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 US disclosed
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 US disclosed
EP-4185381-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B1, HSD17B13 SMN1; SMN2 4508/4885MAPT 2171/4885ALDH1A1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.